Benjamin Auspitz is listed as a director on 2 SEC Form D filings by 1 issuer between Jun 2016 and Jan 2018: Akriveia Therapeutics, LLC (Skillman, NJ — biotechnology — 2016–2018; $4.5M reported sold to 1 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Simon Tomlinson (2 shared filings), Thomas Beck (2 shared filings), David Grayzel (1 shared filing) and Michael Gladstone (1 shared filing).
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Benjamin. Each name links to their own page.
The issuer belongs to the sponsor group Akriveia (2 issuers, $3.2M reported sold, 2016–2023).
What this means A sponsor group is one team that sets up a new company for each deal. Akriveia has 2 companies on file and $3.2M reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Benjamin Auspitz and found 4 differences: Form D filed 21 days after the first sale; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.